Company news
ProMIS Neurosciences Inc. news in 2024
ProMIS Neurosciences Inc.'s news releases, calls and decks from 2024, newest first.
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
November 13, 2024
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
September 11, 2024
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
August 5, 2024
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
July 31, 2024
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
July 25, 2024
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
July 25, 2024
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 13, 2024
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
April 29, 2024
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 8, 2024
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 3, 2024
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
March 31, 2024
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 10, 2024
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
February 21, 2024
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 21, 2024
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 2, 2024